No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 406,678 | 436,911 | 492,387 | 552,007 | 590,231 | 620,768 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 55,584 | 30,752 | 22,444 | 50,473 | 29,454 | 42,661 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.